TGA denies lecanemab as a treatment for early Alzheimer's

Written by Emily J. Thompson, Senior Investment Analyst

Updated: Mar 03 2025

0mins

Eisai's Approval Decline: The Therapeutic Goods Administration of Australia has declined to approve lecanemab as a treatment for early Alzheimer's disease, which is developed by BioArctic partner Eisai.
Future Actions: Eisai is committed to providing access to lecanemab for eligible Australians and is considering options such as seeking a review by the Administrative Review Tribunal.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.